Immunity to SARS-CoV-2 variants of concern

Daniel M Altmann¹, Rosemary J Boyton^{2

3}, Rupert Beale^{4

5}

Affiliations

¹ Department of Immunology and Inflammation, Imperial College London, UK. d.altmann@imperial.ac.uk.
² Department of Infectious Disease, Imperial College London, UK.
³ Lung Division, Royal Brompton and Harefield Hospitals, London, UK.
⁴ The Francis Crick Institute, London, UK.
⁵ Division of Medicine, University College London, London, UK.

Comment

Daniel M Altmann et al. Science. 2021.

. 2021 Mar 12;371(6534):1103-1104.

doi: 10.1126/science.abg7404.

Daniel M Altmann¹, Rosemary J Boyton^{2

3}, Rupert Beale^{4

5}

¹ Department of Immunology and Inflammation, Imperial College London, UK. d.altmann@imperial.ac.uk.
² Department of Infectious Disease, Imperial College London, UK.
³ Lung Division, Royal Brompton and Harefield Hospitals, London, UK.
⁴ The Francis Crick Institute, London, UK.
⁵ Division of Medicine, University College London, London, UK.

No abstract available

Comment on

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
Muik A, Wallisch AK, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Maurus D, Sarkar R, Türeci Ö, Dormitzer PR, Şahin U. Muik A, et al. Science. 2021 Mar 12;371(6534):1152-1153. doi: 10.1126/science.abg6105. Epub 2021 Jan 29. Science. 2021. PMID: 33514629 Free PMC article.